Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis

Jing-jing Lu, Ping Li, Yong Yang, Le Wang, Yan Zhang, Jia-yao Zhu, Xiaoren Zhu, Min-bin Chen

1 Department of Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China,
2 Department of Gastrointestinal Surgery, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China

☯ These authors contributed equally to this work.
* cmb1981@outlook.com

Abstract

Background

The expression of the L-type amino acid transporter 1 (LAT1) plays a significant role in tumor progression. However, it remains unclear whether high LAT1 expression correlates with poor prognosis of solid tumor patients. Here, we conducted a meta-analysis to assess the potential of LAT1 in predicting the prognosis of tumor patients.

Methods and findings

A total of 4,579 cases were analyzed from 35 qualified studies. In patients with solid tumors, elevated expression of LAT1 is associated with poor prognosis (overall survival [OS]: pooled hazard ratio (HR) = 1.848, 95% confidence interval (CI) = 1.620–2.108, \( P < 0.001 \); disease free survival [DFS]: pooled HR = 1.923, 95% CI = 1.585–2.333, \( P < 0.001 \); progression free survival [PFS]: pooled HR = 1.345, 95% CI = 1.133–1.597, \( P = 0.001 \)). Furthermore, in subgroup analysis, we found an association between high LAT1 expression and poor OS in non-small cell lung cancer (HR = 1.554, 95% CI = 1.345–1.794, \( P < 0.001 \)), pancreatic cancer (HR = 2.052, 95% CI = 1.613–2.724, \( P < 0.001 \)) and biliary tract cancer (HR = 2.253, 95% CI = 1.562–3.227, \( P < 0.001 \)).

Conclusion

The results of this meta-analysis indicate the reliability and potential of using LAT1 expression as a predictive biomarker in solid cancers prior to treatment. However, further studies with larger sample sizes would be beneficial for fully evaluating the predictive value of LAT1 expression for clinical applications.
Introduction

The L-type amino acid transporter 1 (LAT1) is a membrane protein responsible for transporting neutral amino acids, including phenylalanine, leucine, valine, etc., as a part of system L for cellular intake of nutrients [1]. LAT1, also known as 4F2 light chain, is connected through a disulfide bond to the membrane-spanning 4F2 heavy chain (CD98) for its functional expression as part of a heterodimeric complex in the plasma membrane [2, 3]. It has been previously reported that LAT1 is associated with the prognosis of tumors.

Amino acid transporters are essential for cell growth and proliferation [1, 4]. The upregulation of LAT1 facilitates the growth of tumor cells [4–9], while selective inhibition of LAT1 inhibits the growth and proliferation of tumor cells [10–16]. It has been reported that LAT1 expression levels positively correlate with cell proliferation (Ki-67 labeling index), p53 expression, VEGF levels as well as poor prognosis of patients in a variety of solid cancers [8, 9, 17–20]. LAT1 transports essential amino acids to provide nutrients for cancer cell growth. Moreover, LAT1 induces rapid dephosphorylation of mTORC1 effectors S6K1 and 4EBP1 through regulation of amino acids such as leucine to activate mTOR signaling pathway, promoting the occurrence of tumors [21, 22].

However, it remains unclear whether LAT1 expression is associated with a worse outcome across solid cancer patients. These conflicting results may be due to the small sample size among individual studies and limitations of current technology. Therefore, we conducted this meta-analysis to evaluate the prognostic value of LAT1 expression as a predictive biomarker with the goal of guiding clinicians and patients in determining the best course of treatment.

Materials and methods

Publication search

Primary literature was collected from electronic databases PubMed, EMBASE and Web of Science for the LAT1 studies until August 10, 2019, with the search terms: (LAT1 OR “L-type amino acid transporter 1” OR SLC7A5 OR 4F2lc OR CD98lc) AND (prognosis OR survival OR predict OR outcome) AND (neoplasms OR neoplasms OR cancer OR tumor OR carcinoma). All publications that met requirements were included as well as eligible studies identified within their references. References cited in the original studies were manually evaluated for inclusion/exclusion criteria. In the event that the study had ongoing investigation of the same patient pool, the largest sample size at the time was included for this meta-analysis.

Inclusion and exclusion criteria

The studies to be involved in this research were determined using the subsequent criteria: (a) evaluated the prognostic status of LAT1 in cancer, (b) provided HRs with 95% confidence intervals (CIs) or provided calculation or charts that displayed clear statistical analysis, (c) divided LAT1 status into ‘positive’ and ‘negative’ or ‘high’ and ‘low’, (d) articles issued in English.

Exclusion criteria: (a) reviews, summary of conference, editorials, letters, case reports, and abstracts, (b) the experiments were conducted in vivo or in vitro, but research design was not patient-based, (c) studies without HRs, 95% CI, or outcomes defined by OS, DFS, PFS, or the K-M survival curves. (d) the follow-up duration was less than 36 months.

Data extraction

Based on the above criteria, authors Lu and Li comprehensively collected relevant data from all qualified publications in a standardized manner. If a consensus could not be reached, the
third author (Chen) independently assessed the data from the initial article to review the discrepancy and agreement was achieved through discussion. The study was based on three outcome endpoints: OS, DFS and PFS. We extracted the following information from the selected papers according to the criteria above, including the name of the first author, country of origin, year of publication, number of patients analyzed, antibody, cancer types, LAT1 detection method, cut-off value, endpoints and Newcastle-Ottawa Scale (NOS). The summary of the included studies can be found in Table 1. For articles plotting prognosis only with Kaplan-Meier curve, survival data was extracted with Engauge Digitiser V4.1, and then HRs and 95% CIs were estimated by Tierney's method [23]. NOS was used to assess the quality of all studies [24]. Studies with NOS scores ranging from 6 to 9 were used for quality control of methodology.

Statistical analysis

The correlation between LAT1 expression and prognosis was assessed by meta-analysis using studies determined eligible by the inclusion criteria. The outcome endpoints (OS, DFS and PFS) were calculated for pooled HRs and 95% CIs. Subgroup analysis was conducted when each subgroup has or exceeds three studies. Higgins’s I² statistic and Cochran’s Q test were used to evaluate statistical heterogeneity [25], and lack of heterogeneity among studies was indicated when P value >0.10 and I²<40%. In accordance with heterogeneity status, we used the random effects model or fixed effects model to merge HR.

This analysis uses Funnel plots and the Egger’s test to assess any potential publication bias [26]. In the event of publication bias, the Duval and Tweedie’s trim and fill method was used to evaluate their impact on the overall effect [27]. Sensitivity analysis also identified potential outliers by omitting each study or specific studies. Stata 14.0 (StataCorp, College Station, TX) was used to conduct statistical analyses. The P values were two-tailed and statistical significant when p<0.05, except for those with statistical heterogeneity.

Results

Demographic characteristics

As shown in the search flowchart (Fig 1), we initially retrieved 107 records in document retrieval databases using a predefined search approach. After reviewing the retrieved titles and abstracts, we excluded 32 articles that described irrelevant endpoints of the 75 articles downloaded as full-text, we excluded 40 studies that were unrelated to prognosis (15 articles), had no prognosis data (11 articles), where the prognosis was related to CD98 (3 articles), LAT2 (1 article), LAT1 and ASCT2 co-expression (3 articles), status of LAT1 RNA in cancers (2 articles), or were a description about LAT1 detection technology (5 articles). The remaining 35 articles that reached our meta-analysis criteria were selected to evaluate LAT1 expression and solid cancer prognosis of patients. To assess the relevance between LAT1 and the prognosis of solid cancer, 4,579 eligible patients were selected for this analysis. Sample cases ranged from 21 to 321. Of the 35 prognostic studies, 35 were on OS, 5 on DFS, and 7 on PFS. Most studies were performed in Japan (n = 33), followed by China (n = 1) and Thailand (n = 1), respectively. As for the cancer type, 11 studies evaluated lung cancer, of which 10 were non-small cell lung cancer, pancreatic cancer and biliary tract cancer each have 3 studies, hepatocellular carcinoma, ovarian tumor, gastric cancer, prostatic cancer and colorectal cancer each have 2 studies, breast cancer, multiple myeloma, tongue cancer, laryngeal squamous cell carcinoma, cutaneous melanoma, cutaneous angiosarcoma, malignant pleural mesothelioma and adenoid cystic carcinoma each have 1 study.
Table 1. Characteristics of studies included in the meta-analysis.

| Author            | Year | Country | Cases | Cancer type                        | Antibody                              | Method                     | Cut-off value                | Endpoints | NOS |
|-------------------|------|---------|-------|------------------------------------|----------------------------------------|----------------------------|-----------------------------|-----------|-----|
| Imai, H. [33]     | 2009 | Japan   | 282   | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 7   |
| Kaira, K. [20]    | 2008 | Japan   | 321   | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 8   |
| Kaira, K. [34]    | 2009 | Japan   | 139   | pulmonary adenocarcinoma           | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 8   |
| Kaira, K. [35]    | 2009 | Japan   | 220   | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 8   |
| Kaira, K. [36]    | 2010 | Japan   | 188   | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 7   |
| Kaira, K. [37]    | 2010 | Japan   | 59    | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 8   |
| Furuya, M. [8]    | 2012 | Japan   | 50    | breast cancer                      | mouse anti-LAT1 antibody (1:1 dilution)  | ICH                        | scores of 2, 3, 4            | OS, DFS   | 7   |
| Kaira, K. [42]    | 2012 | Japan   | 97    | pancreatic cancer                  | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores of 3, 4              | OS, PFS   | 8   |
| Yanagisawa, N. [43] | 2012 | Japan   | 66    | pancreatic ductal adenocarcinomas | anti-LAT1                              | ICH                        | scores of 6–9               | OS        | 9   |
| Kaira, K. [45]    | 2013 | Japan   | 139   | biliary tract cancer               | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores of 3, 4              | OS, PFS   | 7   |
| Kaira, K. [17]    | 2013 | Japan   | 30    | adenoid cystic carcinoma           | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores of 3, 4              | OS, PFS   | 7   |
| Isoda, A. [57]    | 2014 | Japan   | 100   | multiple myeloma                   | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores of 2+, 3+            | OS, PFS   | 8   |
| Namikawa, M [48]  | 2015 | Japan   | 84    | hepatocellular carcinoma           | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores > 1                  | OS        | 7   |
| Toyoda, M.[58]    | 2014 | Japan   | 85    | tongue cancer                      | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores of 3, 4              | OS, PFS   | 6   |
| Yanagisawa, N. [46] | 2014 | Japan   | 134   | bile duct adenocarcinomas          | anti-LAT1                              | ICH                        | score of 9                  | OS        | 7   |
| Kaira, K. [50]    | 2015 | Japan   | 142   | ovarian tumors                     | mouse anti-LAT1 antibody (1:800 dilution) | ICH                        | scores of 2, 3, 4            | OS        | 8   |
| Nikkuni, O. [59]  | 2015 | Japan   | 73    | laryngeal squamous cell carcinoma  | mouse anti-LAT1 antibody (1:800 dilution) | ICH                        | scores of 4, 5              | OS        | 7   |
| Shimizu, A.[60]   | 2015 | Japan   | 128   | cutaneous melanoma                 | mouse anti-LAT1 antibody (1:800 dilution) | ICH                        | scores of 2, 3, 4            | OS, DFS   | 8   |
| Shimizu, A.[61]   | 2017 | Japan   | 52    | cutaneous angiosarcoma             | mouse anti-LAT1 antibody (1:800 dilution) | ICH                        | scores of 3, 4              | OS, PFS   | 8   |
| Imai, H. [16]     | 2010 | Japan   | 51    | non-small cell lung cancer         | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 8   |
| Ichinoe, M.[52]   | 2011 | Japan   | 87    | gastric carcinomas                 | anti-LAT1                              | ICH                        | scores of 6–9               | OS        | 8   |
| Kaira, K. [38]    | 2009 | Japan   | 84    | squamous cell carcinoma of the lung | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 9   |
| Kaira, K. [62]    | 2011 | Japan   | 21    | Malignant pleural mesothelioma     | rabbit anti-LAT1 antibody (1:3200 dilution) | ICH                        | >10% of tumor cells         | OS        | 7   |
| Takeuchi, K. [39] | 2010 | Japan   | 295   | non-small cell lung cancer         | mouse anti-LAT1 antibody (1:20 dilution)  | ICH                        | >10% of tumor cells         | OS        | 8   |
| Li, J. [49]       | 2013 | China   | 148   | hepatocellular                     | goat anti-LAT1                        | ICH                        | Si > 4                     | OS        | 8   |
| Yazawa, T.[40]    | 2015 | Japan   | 222   | lung adenocarcinoma                | mouse anti-LAT1 antibody (1:3200 dilution) | ICH                        | scores ≥ 2                  | OS        | 9   |
| Yanagisawa, N. [54] | 2015 | Japan   | 109   | prostatic cancer                   | mouse anti-LAT1                      | ICH                        | scores of 4–9              | OS        | 8   |
| Ichinoe, M. [53]  | 2015 | Japan   | 64    | gastric carcinoma                  | anti-LAT1                              | ICH                        | scores of 6–9               | OS        | 8   |

(Continued)
Table 1. (Continued)

| Author       | Year | Country | Cases | Cancer type                  | Antibody                  | Method      | Cut-off value | Endpoints | NOS |
|--------------|------|---------|-------|-------------------------------|---------------------------|-------------|---------------|-----------|-----|
| Yothaisong, S. [47] | 2015 | Thailand | 178   | cholangiocarcinogenesis       | anti-LAT1                 | ICH         | scores ≥ 4    | OS        | 8   |
| Altan, B. [44] | 2018 | Japan   | 110   | pancreatic ductal adenocarcinoma | rabbit anti-LAT1 antibody (1:5000 dilution) | ICH         | scores of 3, 4 | OS, DFS   | 8   |
| Hayase, S. [55] | 2017 | Japan   | 210   | colorectal cancer             | mouse anti-LAT1 antibody (1:200 dilution) | ICH         | scores of 3, 4 | OS        | 9   |
| Kaira, K. [41]  | 2019 | Japan   | 105   | pulmonary pleomorphic carcinoma | rabbit anti-LAT1 antibody (1:5000 dilution) | ICH         | scores of 4   | OS, DFS   | 8   |
| Ogawa, H. [56]  | 2019 | Japan   | 147   | colorectal cancer             | rabbit anti-LAT1 antibody (1:5000 dilution) | ICH         | scores of 4   | OS, DFS   | 9   |
| Sato, K. [51]   | 2019 | Japan   | 245   | ovarian carcinoma             | rabbit anti-LAT1 antibody (1:800 dilution) | ICH         | scores of 3, 4 | OS, PFS   | 9   |
| Sakata, T. [7]  | 2009 | Japan   | 114   | prostate cancer               | mouse anti-LAT1 antibody (1:1 dilution) | ICH         | scores of 4–9 | OS        | 8   |

Abbreviations: ICH: Immunohistochemistry; NOS: Newcastle-Ottawa Scale; OS: overall survival; DFS: disease free survival; PFS: progression free survival.

https://doi.org/10.1371/journal.pone.0233629.t001

Fig 1. The flow chart of the selection process in our meta-analysis.

https://doi.org/10.1371/journal.pone.0233629.g001
Evidence synthesis

This meta-analysis focused on the relationship between LAT1 status and the prognosis of cancer patients. In this study, the p value of heterogeneity test for OS was 0.004, and the I² value was 43.0%. The random effect model was used. The results showed that there was a significant
The correlation between LAT1 high expression solid cancers and poor OS (pooled HR = 1.848, 95% CI = 1.620–2.108, \(P < 0.001\)) (Fig 2). Examining five DFS, the \(P\) value and \(I^2\) value of heterogeneity test report were 0.052 and 57.4%, respectively. The pooled HR and 95% confidence interval (CI) were calculated using the random effect model. The results suggested that LAT1 high expression was associated with poor DFS (pooled HR = 1.923, 95% CI = 1.585–2.333, \(P < 0.001\)) (Fig 3). Seven PFS databases were included in the meta-analysis, and the \(P\) value and \(I^2\) value of heterogeneity test report were 0.182 and 32.2%, respectively. The pooled HR and 95% confidence interval (CI) were calculated by using the fixed effect model. The results suggested that high LAT1 expression was associated with poor PFS (pooled HR = 1.345, 95% CI = 1.133–1.597, \(P = 0.001\)) (Fig 4).

To explore the source of heterogeneity, subgroup analysis was performed when more than 3 articles participated in each type. The results of subgroup analysis are shown in Table 2. In the cancer subgroups, there was a significant relationship between high LAT1 expression and poor OS in solid tumors observed in patients with lung cancer (HR = 1.573, 95% CI = 1.309–1.890, \(P < 0.001\)), non-small cell lung cancer (HR = 1.554, 95% CI = 1.345–1.794, \(P < 0.001\)), pancreatic cancer (HR = 2.052, 95% CI = 1.613–2.724, \(P < 0.001\)) and biliary tract cancer (HR = 2.253, 95% CI = 1.562–3.227, \(P < 0.001\)). When analyzed by the statistical method of
LAT1 prognosis, the relationship was still found in the multivariate analysis (OS: HR = 2.052, 95% CI = 1.770–2.378, \( P < 0.001 \); PFS: HR = 1.547, 95% CI = 1.089–2.199, \( P = 0.015 \); DFS: HR = 1.884, 95% CI = 1.196–2.968, \( P = 0.006 \)) and univariate analysis (OS: HR = 1.439, 95% CI = 1.153–1.797, \( P = 0.001 \)). Furthermore, subgroup analysis from cut off found that >10% of tumor cells (OS: HR = 1.786, 95% CI = 1.503–2.122, \( P < 0.001 \)), scores of 3, 4 (OS: HR = 1.955, 95% CI = 1.493–2.558, \( P < 0.001 \); PFS: HR = 1.349, 95% CI = 1.027–1.773, \( P = 0.032 \)), scores of 6–9 (OS: HR = 1.792, 95% CI = 1.141–2.812, \( P = 0.011 \)), other cut off value (OS: HR = 2.277, 95% CI = 1.557–3.331, \( P < 0.001 \)), all of the results showed a poorer prognosis. Moreover, in the ethnicity subgroup, most of studies were from Asian, the results shown high LAT1 expression were all associated with poorer prognosis (OS: HR = 1.848, 95% CI = 1.620–2.108, \( P < 0.001 \); PFS: HR = 1.345, 95% CI = 1.133–1.597, \( P = 0.001 \); DFS: HR = 1.923, 95% CI = 1.585–2.333, \( P < 0.001 \)).

**Publication bias and sensitivity analysis**

Begg’s funnel plot and Egger’s test were used to detect publication bias of the above literature. There was no evidence of significant asymmetry on the funnel plot, and Egger’s test found no
publication bias ($p<0.05$) (Fig 5). Our sensitivity analysis confirmed the impact of these results. None of the individual studies had guided this meta-analysis and eliminating any single study had no significant effect on the final results (Fig 6).

**Discussion**

There is increasing evidence showing that LAT1 plays a significant role in promoting tumor cell growth and proliferation [2, 3, 28, 29]. By interfering with the expression of LAT1, Hayashi K et al. demonstrated that the proto-oncogene c-Myc binds to the LAT1 promoter sequence to accelerate its expression [30]. Furthermore, the heterodimeric complex formed by the binding of LAT1 and CD98 plays a significant role in integrin signaling of cancer cells, sequentially activating the phosphatidylinositide 3-kinase/AKT (PI3K/AKT), p130CAS and focal adhesion kinase (FAK) signaling pathway [31, 32]. The relationship of LAT1 expression levels and prognosis of solid cancer patients is difficult to determine from individual clinical reports, as they involve small sample sizes.

To our knowledge, this is the first complete study demonstrating the prognosis significance of LAT1 status in solid cancers. In this meta-analysis, we examined 16 cancer types, including lung cancer [16, 20, 33–41], pancreatic cancer [42–44], biliary tract cancer [45–47],...
Fig 5. Begg's funnel plots for the studies involved in the meta-analysis. A. overall survival B: progression free survival. C. disease free survival. Abbreviations: loghr, logarithm of HRs; s.e., standard error.

https://doi.org/10.1371/journal.pone.0233629.g005
hepatocellular carcinoma [48, 49], ovarian tumor [50, 51], breast cancer [8], gastric carcinomas [52, 53], prostatic cancer [7, 54], colorectal cancer [55, 56], adenoid cystic carcinoma [17], multiple myeloma [57], tongue cancer [58], laryngeal squamous cell carcinoma [59], cutaneous melanoma [60], cutaneous angiosarcoma [61] and malignant pleural mesothelioma [62]. We assessed the survival data of 4,579 cancer patients with regard to LAT1 status, and 35 different studies were systematically included. In summary, the results clearly indicate that LAT1 overexpression is an indicator for poor prognosis in solid cancer, with poor OS (pooled HR = 1.848, 95% CI = 1.620–2.108, \( P < 0.001 \)), poor DFS (pooled HR = 1.923, 95% CI = 1.585–2.333, \( P < 0.001 \)) and poor PFS (pooled HR = 1.345, 95% CI = 1.133–1.597, \( P = 0.001 \)).

In our paper, we also used subgroup analysis to illustrate the relationship between high expression of LAT1 and prognosis. The subgroup analysis was conducted by at least 3 articles participated in each type including cancer type, HR estimation, cut off value and ethnicity. The significant relationship was still found in these subgroup.

The results of our current analysis may be affected by a number of limitations. First, the meta-analysis may be influenced by the exclusion of articles that are not published in English as well as articles that are proceedings or books. Despite our rigorous search and attempts to obtain unpublished information, some data loss was inevitable. Second, most of the studies involved were retrospective, with positive results more likely to be published than negative. Third, although the expression of LAT1 was detected by immunohistochemistry in all studies, the antibody concentration and cut-off value were different for each study, which could lead to some deviation in the combined analysis. Lastly, LAT1 is typically co-expressed with CD98, which may play a synergistic role in the development and progression of tumors.

Despite these limitations, this meta-analysis has several advantages. This is the first comprehensive statistical study of LAT1 that evaluates the prognostic significance of LAT1 status in solid cancers before treatment. We collected 4,579 patients from the limited subsets, which represented a large number of cases and significantly improved the statistical value in this analysis. Additionally, no publication biases were detected, suggesting that the results of the analysis are impartial.

The results suggest that before tumor treatment, the expression of LAT1 can be used to predict tumor patient outcome. Nevertheless, to verify our finding more accurately, more comprehensive studies will be required to evaluate the predictive value of high LAT1 expression for future clinical practice.

**Supporting information**

S1 Checklist. PRISMA 2009 checklist.

(DOC)

**Acknowledgments**

We would like to acknowledge the participants for the preliminary survey, data collection and analysis. We would also like to thank those for checking and reviewing this paper.

**Author Contributions**

Conceptualization: Jing-jing Lu, Min-bin Chen.
Data curation: Jing-jing Lu, Ping Li, Yong Yang.
Formal analysis: Jing-jing Lu, Ping Li.
Funding acquisition: Min-bin Chen.
Investigation: Jing-jing Lu, Ping Li, Yong Yang, Le Wang.
Methodology: Jing-jing Lu, Ping Li.
Project administration: Min-bin Chen.
Supervision: Jing-jing Lu, Min-bin Chen.
Validation: Jing-jing Lu, Ping Li, Yong Yang.
Visualization: Jing-jing Lu.
Writing – original draft: Jing-jing Lu, Ping Li.
Writing – review & editing: Jing-jing Lu, Ping Li, Yong Yang, Le Wang, Yan Zhang, Jia-yao Zhu, Xiao-ren Zhu, Min-bin Chen.

References

1. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiological Reviews. 1990; 70(1):43–77. https://doi.org/10.1152/physrev.1990.70.1.43 PMID: 2404290
2. Kanai Y, Segawa H, Miyamoto KI, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of F2 antigen (CD98). Journal of Biological Chemistry. 1998; 273(37):23629–32. https://doi.org/10.1074/jbc.273.37.23629 PMID: 9726963
3. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. BBA—Biomembranes. 2001; 1514(2):291–302. https://doi.org/10.1016/s0005-2736(01)00384-4 PMID: 11557028
4. Mcgivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochemical Journal. 1994; 299 (Pt 2)(299 (Pt 2)):321–34. https://doi.org/10.1042/bj2990321 PMID: 8172990
5. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. Journal of surgical oncology. 2005; 90(4):233–8. https://doi.org/10.1002/jso.20257 PMID: 15906366
6. Sakata T, Ferdous G, T, Satoh T, Baba S, Muto T, Ueno A, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathology international. 2010; 59(1):7–18. https://doi.org/10.1111/j.1440-1827.2008.02319.x PMID: 19120877
7. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathology international. 2009; 59(1):7–18. https://doi.org/10.1111/j.1440-1827.2008.02319.x PMID: 19120877
8. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer science. 2012; 103(2):382–9. https://doi.org/10.1111/j.1349-7006.2011.02151.x PMID: 22077314
9. Kyoichi K, Noboru O, Toshiaki K, Kazuo N, Yasuhi O, Takehiro O, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. American journal of translational research. 2011; 3(5):468–78. PMID: 22046488
10. Huttunen KM, Gynther M, Huttunen J, Puris E, Spicer JA, Denny WA. A Selective and Slowly Reversible Inhibitor of L-Type Amino Acid Transporter 1 (LAT1) Potentiates Anti-Proliferative Drug Efficacy in Cancer Cells. Journal of medicinal chemistry. 2016; 59(12):acs.jmedchem.6b00190. https://doi.org/10.1021/acs.jmedchem.6b00190 PMID: 27253989
11. Koji O, Noriko H, Hiroshi E, Kunio S, Kenji T, Michio Y, et al. L-type amino-acid transporter 1 inhibitors inhibit tumor cell growth. Cancer science. 2010; 101(1):173–9. https://doi.org/10.1111/j.1349-7006.2009.01386.x PMID: 19900191
12. Shennan DB, Jean T. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncology reports. 2008; 20(4):885–9. PMID: 18913831
13. Park NS, Kim SG, Kim HK, Moon SY, Kim CS, Cho SH, et al. Characterization of amino acid transport system L in HTB-41 human salivary gland epidermoid carcinoma cells. Anticancer research. 2008; 28(5A):2649–55. PMID: 19035290

14. Kim C, Park KJ, Park JR, Kanai Y, Endou H, Park J, et al. The RNA Interference of Amino Acid Transporter LAT1 Inhibits the Growth of KB Human Oral Cancer Cells. Anticancer research. 2006; 26(4B):2943. PMID: 16886618

15. Chun Sung K, Seon-Ho C, Sung CH, Sook-Young L, Hitoshi E, Yoshikatsu K, et al. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biological & pharmaceutical bulletin. 2008; 31(6):1096–100. https://doi.org/10.1248/bpb.31.1096 PMID: 18520037

16. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer research. 2010; 30(12):4819–28. PMID: 21187458

17. Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, et al. Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathology oncology research: POR. 2013; 19(4):649–56. https://doi.org/10.1007/s12253-013-9624-2 PMID: 23516127

18. Kyoichi K, Noboru O, Toshiaki T, Kazuo N, Yasuhisa O, Takehiro O, et al. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer research. 2011; 31(12):4075–82. PMID: 22199264

19. Kyoichi K, Toshiaki T, Masato A, Hiroaki A, Kazuo N, Yasuhisa O, et al. CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. Oncology reports. 2010; 24(4):861. https://doi.org/10.3892/or.2010.861 PMID: 20811665

20. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

21. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

22. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

23. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

24. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

25. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

26. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

27. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116

28. Imai H, Kaira K, Oriuchi N, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. British journal of cancer. 2008; 98(4):742–8. https://doi.org/10.1038/sj.bjc.6604235 PMID: 18253116
33. Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Hana K, et al. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology. 2009; 54(7):804–13. https://doi.org/10.1111/j.1365-2559.2009.03300.x PMID: 19635099

34. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung cancer. 2009; 66(1):120–6. https://doi.org/10.1016/j.lungcan.2008.12.015 PMID: 19171406

35. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Annals of surgical oncology. 2009; 16(12):3473–81. https://doi.org/10.1245/s10434-009-0685-0 PMID: 19777189

36. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Experimental and therapeutic medicine. 2010; 1(5):799–808. https://doi.org/10.3892/etm.2010.117 PMID: 22993604

37. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nuclear medicine and biology. 2010; 37(8):911–6. https://doi.org/10.1016/j.nucmedbio.2010.06.004 PMID: 21055621

38. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer science. 2009; 100(2):248–54. https://doi.org/10.1111/j.1349-7006.2008.01029.x PMID: 19068093

39. Takeuchi K, Ogata S, Nakanishi K, Ozeki Y, Hiroi S, Tominaga S, et al. LAT1 expression in non-small cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases). Lung cancer. 2010; 68(1):58–65. https://doi.org/10.1016/j.lungcan.2009.05.020 PMID: 19559497

40. Yazawa T, Shimizu K, Kaira K, Nagashima T, Ohtaki Y, Atsumi J, et al. Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. American journal of translational research. 2015; 7(6):1126–39. PMID: 26279756

41. Kaira K, Kawashima O, Endoh H, Imai K, Goto Y, Kamiyoshiihara M, et al. Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human pathology. 2019; 84:142–9. https://doi.org/10.1016/j.humpath.2018.09.020 PMID: 30300664

42. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, et al. Prognostic significance of L-type amino acid transporter 1 expression in surgically resected pancreatic cancer. British journal of cancer. 2012; 107(4):632–8. https://doi.org/10.1038/bjc.2012.310 PMID: 22805328

43. Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W, et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. Journal of clinical pathology. 2012; 65(11):1019–23. https://doi.org/10.1136/jclinpath-2012-200826 PMID: 22813728

44. Altan B, Kaira K, Watanabe A, Kubo N, Bao P, Dolgormaa G, et al. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer chemotherapy and pharmacology. 2018; 81(1):141–53. https://doi.org/10.1007/s00280-017-3477-4 PMID: 29149426

45. Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC cancer. 2013; 13:482. https://doi.org/10.1186/1471-2407-13-482 PMID: 24131658

46. Yanagisawa N, Hana K, Nakada N, Ichinoe M, Koizumi W, Endou H, et al. High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Cancer medicine. 2014; 3(5):1246–55. https://doi.org/10.1002/cam4.272 PMID: 24890221

47. Yothaisong S, Namvat N, Yongvanit P, Khuntikeo N, Puapairoj A, Jutabha P, et al. Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. Parasitology international. 2017; 66(4):471–8. https://doi.org/10.1016/j.parint.2015.11.011 PMID: 26657242

48. Namikawa M, Kakizaki S, Kaira K, Tjojima H, Yamazaki Y, Horiguchi N, et al. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatology research: the official journal of the Japan Society of Hepatology. 2015; 45(9):1014–22. https://doi.org/10.1002/hepr.2015.020 PMID: 25297701

49. Li J, Qiang J, Chen SF, Wang X, Fu J, Chen Y. The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma. Tumour biology: the journal of the International Society for
50. Kaira K, Nakamura K, Hirakawa T, Imai H, Tominaga H, Oriuchi N, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. American journal of translational research. 2015; 7(6):1161–71. PMID: 26279759

51. Sato K, Miyamoto M, Takano M, Furuya K, Tsuda H. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Archiv: an international journal of pathology. 2019; 474(6):701–10. https://doi.org/10.1007/s00428-019-02520-0 PMID: 30637450

52. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathology international. 2011; 61(5):281–9. https://doi.org/10.1111/j.1440-1827.2011.02650.x PMID: 21501294

53. Ichinoe M, Yanagisawa N, Mikami T, Hana K, Nakada N, Endou H, et al. L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling. Pathology, research and practice. 2015; 211(7):533–8. https://doi.org/10.1016/j.prp.2015.03.007 PMID: 25908107

54. Yanagisawa N, Sato T, Hana K, Ichinoe M, Nakada N, Endou H, et al. L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management. Cancer biomarkers: section A of Disease markers. 2015; 15(4):365–74. https://doi.org/10.3233/CBM-150486 PMID: 25835180

55. Hayase S, Kumamoto K, Saito K, Kofunato Y, Sato Y, Okayama H, et al. L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Oncology letters. 2017; 14(6):7410–6. https://doi.org/10.3892/ol.2017.7148 PMID: 29344181

56. Ogawa H, Kaira K, Motegi Y, Yokobori T, Takada T, Katoh R, et al. Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. Anticancer research. 2019; 39(5):2535–43. https://doi.org/10.21873/anticanres.13375 PMID: 31092450

57. Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, et al. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer science. 2014; 105(11):1496–502. https://doi.org/10.1111/cas.12529 PMID: 25220100

58. Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. British journal of cancer. 2014; 110(10):2506–13. https://doi.org/10.1038/bjc.2014.176 PMID: 24762957

59. Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, et al. Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. Pathology oncology research: POR. 2015; 21(4):1175–81. https://doi.org/10.1007/s12253-015-9954-3 PMID: 26224742

60. Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, et al. Prognostic significance of L-type amino-acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma research. 2015; 25(5):399–405. https://doi.org/10.1097/CMR.0000000000000181 PMID: 26237765

61. Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Tominaga H, et al. Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma. Neoplasma. 2017; 64(2):283–8. https://doi.org/10.4149/neop_2017_216 PMID: 28032681

62. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, et al. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer research. 2011; 31(12):4075–82. PMID: 22199264